Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) saw a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,820,000 shares, an increase of 32.8% from the August 31st total of 1,370,000 shares. Approximately 4.9% of the shares of the company are sold short. Based […]
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Thursday, Benzinga reports. They currently have a $4.00 price objective on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 148.45% from the company’s previous close. […]
StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Free Report) in a research note published on Thursday. The brokerage issued a sell rating on the stock. Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald upped their price target on shares of Corvus Pharmaceuticals from $2.00 to $4.00 in […]
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $2.56 and traded as low as $2.04. Corvus Pharmaceuticals shares last traded at $2.24, with a volume of 113,815 shares changing hands. Analysts Set […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report)’s share price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $2.56 and traded as low as $2.04. Corvus Pharmaceuticals shares last traded at $2.24, with a volume of 113,815 shares changing hands. Analyst Upgrades […]